Acad Radiol

1. ZHUANG J, Xie Y, Chen Y, Zheng W, et al
   Radiomics and Deep Learning Models Based on Manual and Semi-automatic Segmentation of Ultrasound Images for HER2 Prediction in Bladder Cancer.
   Acad Radiol. 2026 Sep 18:S1076-6332(26)00715-4. doi: 10.1016/j.acra.2026.
   

   >> Share

   
   

   
   Adv Radiat Oncol

2. CHAN L, Anzela A, Do V, Wong K, et al
   Dose-Escalated Radiation Therapy for Muscle-Invasive Bladder Cancer: A Retrospective Analysis.
   Adv Radiat Oncol. 2026;11:102156.
   

   >> Share

   
   

   
   Am J Surg Pathol

3. LI H, Akbari A, Schuler M, Salgado Esteves R, et al
   Giant Cell Urothelial Carcinoma: Morphometric Insights and Associations With Aggressive Clinical Features.
   Am J Surg Pathol. 2026;50:1184-1194.
   

   >> Share

   
   

   
   Ann Surg Oncol

4. XING Q, Wei YB, Wang X, Hao HF, et al
   Comparison Study of Inverted-Nipple Ureteroneocystostomy and Direct Anastomosis in U-Shaped Orthotopic Neobladder Reconstruction.
   Ann Surg Oncol. 2026;33:9505-9516.
   

   >> Share

   
   

   
   Biochem Pharmacol

5. WAN W, Wei F, Yang L, Yu X, et al
   AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer.
   Biochem Pharmacol. 2026 Sep 18:118486. doi: 10.1016/j.bcp.2026.118486.
   

   >> Share

   
   

   
   Bladder Cancer

6. SHULMAN MJ, Lee VS, Roh JM, Kwan ML, et al
   Guideline-recommended post-operative intravesical chemotherapy and cystoscopic surveillance among patients with low- and intermediate-risk non-muscle invasive bladder cancer.
   Bladder Cancer. 2026;12:23523735261487765.
   

   >> Share

   
   

   
   BMJ Case Rep

7. BRANCHER AJ, Brough S, Gallappatige A, Tempo J, et al
   Muscle-invasive urothelial carcinoma of the bladder in a direct inguinal hernia.
   BMJ Case Rep. 2026;19:e270611.
   

   >> Share

   
   

   
   Br J Cancer

8. SU X, Jin K, Zeng H, Liu Z, et al
   TP53 mutation-biased CD8(+) T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.
   Br J Cancer. 2026;135:1131-1139.
   

   >> Share

   
   

   
   Cancer Cell Int

9. BERNDT-PAETZ M, Nurnberger S, Gonsior S, Paczek-Hippe E, et al
   Enhanced survival through repeated photodynamic therapy and almost complete tumor regression by prior radiation therapy in an orthotopic rat bladder cancer model.
   Cancer Cell Int. 2026;26:315.
   

   >> Share

   
   

   
   Cancer Lett

10. LIU K, Bao H, Li G, Ran W, et al
    Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study.
    Cancer Lett. 2026 Sep 18:218853. doi: 10.1016/j.canlet.2026.218853.
    

    >> Share

    
    

    
    Cancer Sci

11. HIROSUNA K, Nishimura K, Sakamoto M, Tokushige S, et al
    Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer.
    Cancer Sci. 2026 Sep 13:10.1111/cas.70534. doi: 10.1111/cas.70534.
    

    >> Share

    
    

    
    Cancers (Basel)

12. DE MAESENEER D, Decruyenaere A, Van der Meulen J, Loontiens S, et al
    Long-Term Outcomes and Paired Immune and Genomic Exploratory Analyses After Neoadjuvant Dose-Dense MVAC in Muscle-Invasive Bladder Cancer: A Single-Centre Case Series.
    Cancers (Basel). 2026;18:2839.
    

    >> Share

    
    
13. POLITO MG, Sisca L, Caruso D, Cosimati A, et al
    Circulating Tumor DNA in Bladder Cancer: Current Clinical Evidence and Emerging Multi-Omics Perspectives-A Narrative Review.
    Cancers (Basel). 2026;18:2816.
    

    >> Share

    
    
14. ZHANG B, Chang H, Wang C, Chang W, et al
    The MAZ-POLD1 Signaling Axis Drives Cisplatin Resistance in Bladder Cancer by Activating DNA Damage Repair.
    Cancers (Basel). 2026;18:2892.
    

    >> Share

    
    

    
    Cell Rep Med

15. OLSON DJ, Liu BA, Younan P, Blahnik-Fagan G, et al
    Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.
    Cell Rep Med. 2026;7:103021.
    

    >> Share

    
    

    
    Chemotherapy

16. IKEDA M, Ichikawa S, Ito S, Okumura K, et al
    Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Case Series.
    Chemotherapy. 2026;71:1-6.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

17. LOTAN Y, Raut M, Zhang S, Lai Y, et al
    Real-World Clinical Outcomes Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin: A SEER-Medicare Analysis.
    Clin Genitourin Cancer. 2026 Aug 5:102641. doi: 10.1016/j.clgc.2026.102641.
    

    >> Share

    
    
18. KIM HJ, Park W, Kim YS, Kim JS, et al
    Definitive Chemoradiotherapy Versus Radical Cystectomy for Small Cell Carcinoma of the Bladder: A Multicenter Retrospective Study.
    Clin Genitourin Cancer. 2026;24:102642.
    

    >> Share

    
    
19. RICCIARDI G, Ballato M, Tralongo P, Fiorentino V, et al
    Detection of FGFR Alterations in Urothelial Carcinoma: Current Diagnostic Methodologies, Technical Considerations and Future Perspectives.
    Clin Genitourin Cancer. 2026;24:102644.
    

    >> Share

    
    
20. LI J, Fredette J, Dhanikonda N, Jhaveri M, et al
    Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response.
    Clin Genitourin Cancer. 2026;24:102631.
    

    >> Share

    
    
21. SANAGAWA A, Kato H, Inoue T, Iwamoto T, et al
    Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2026;24:102617.
    

    >> Share

    
    
22. SCHNEIDEWIND L, Kranz J, Zengerling F, Neumann T, et al
    Sex-Specific Differences in Disease-Free, Progression-Free and Overall Survival Following Enfortumab Vedotin Therapy for Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
    Clin Genitourin Cancer. 2026;24:102611.
    

    >> Share

    
    

    
    Clin Transl Med

23. CHEN H, Ji S, Wu P, Liu J, et al
    Pyrroline-5-carboxylate reductase 1 interacts with Nudix hydrolase 5 to drive bladder cancer malignant progression via activation of the APOE/JAK2/STAT3 signalling axis.
    Clin Transl Med. 2026;16:e70840.
    

    >> Share

    
    

    
    Comb Chem High Throughput Screen

24. CHEN L, Long X, Yang J
    Diosmetin Inhibits Bladder Cancer through Suppression of the PI3K-AKT Signaling Pathway and Activation of the p53 Signal Pathway Revealed by Network Pharmacology and In Vitro Experimental Verification.
    Comb Chem High Throughput Screen. 2026.
    

    >> Share

    
    

    
    Diagnostics (Basel)

25. URRARO F, Giordano N, Patane V, Brunese MC, et al
    The Stalk Sign in Bladder Cancer: CEUS Versus MRI.
    Diagnostics (Basel). 2026;16:2687.
    

    >> Share

    
    
26. HUANG Y, Ji Y, Yang X, Zhao Q, et al
    Post-Treatment NLR and SII Associations with Response and Progression-Free Survival After Neoadjuvant Disitamab Vedotin Plus PD-1 Blockade in Muscle-Invasive Bladder Cancer: A Real-World Cohort Study.
    Diagnostics (Basel). 2026;16:2802.
    

    >> Share

    
    

    
    ESMO Real World Data Digit Oncol

27. UUNK FM, Bosveld J, Boormans JL, van der Heijden AG, et al
    Extended cancer registry data for real-world evidence in bladder cancer: an update on the Prospective Bladder Cancer Infrastructure.
    ESMO Real World Data Digit Oncol. 2026;13:100772.
    

    >> Share

    
    

    
    Eur Urol

28. GIANNATEMPO P, Cerbone L, Calabro F
    Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, Begona P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Eng
    Eur Urol. 2026 Sep 18:S0302-2838(26)02368-7. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Eur Urol Oncol

29. CONTIERI R, Hurle R
    Reply to Roberto Mario Scarpa's Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer:
    Eur Urol Oncol. 2026 Sep 16:S2588-9311(26)00248.
    

    >> Share

    
    

    
    Eur Urol Open Sci

30. FRASLIN AM, Benhamou S, Lebret T, Neuzillet Y, et al
    Longitudinal Economic Burden for Non-Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database.
    Eur Urol Open Sci. 2026;92:28-35.
    

    >> Share

    
    

    
    Exp Hematol Oncol

31. YU S, Wang Y, Feng D, Dai X, et al
    Multimodal AI and single-cell transcriptomics integrate to construct a histopathological prognostic model for bladder cancer, revealing the RTN3-glycolysis axis in chemoresistance.
    Exp Hematol Oncol. 2026;15:93.
    

    >> Share

    
    

    
    Front Med (Lausanne)

32. HAN P, Yang X, Li Q, Lu P, et al
    From hematuria warning to precision immunotherapy: an AI-assisted cross-platform analysis of bladder cancer information on social media.
    Front Med (Lausanne). 2026;13:1910134.
    

    >> Share

    
    
33. CICVARIC A, Glavas Tahtler J, Pavlovic O, Dias C, et al
    Perioperative cognitive dysfunction in bladder cancer patients, causal factors, and possible interventions.
    Front Med (Lausanne). 2026;13:1883877.
    

    >> Share

    
    

    
    Front Oncol

34. HOU Z, Ji M, Peng F, Chen Y, et al
    Case Report: Solitary right thigh skin metastasis of bladder cancer misdiagnosed as erysipelas with literature review.
    Front Oncol. 2026;16:1825362.
    

    >> Share

    
    
35. WAN D, Li Y, Dong Z, Dai C, et al
    Performance evaluation of large language models in bladder cancer patient education Q&A: a cross-sectional study.
    Front Oncol. 2026;16:1909227.
    

    >> Share

    
    
36. SUN J, Wang Z, Yang M, Tan Z, et al
    MRI-derived features reveal recurrence heterogeneity in VI-RADS 2 non-muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1921569.
    

    >> Share

    
    
37. THALAMBEDU N, Vasipalli K, Sampath Kumar N, Vellanki S, et al
    Immunotherapy role in bladder cancer treatment: a review of literature.
    Front Oncol. 2026;16:1908307.
    

    >> Share

    
    

    
    Int J Mol Sci

38. LIU Y, Li Z, Kuang Y, Chen K, et al
    1-Hydroxypyrene Promotes Bladder Cancer Progression and Tumor-Associated Immunosuppression via MIF.
    Int J Mol Sci. 2026;27:7778.
    

    >> Share

    
    
39. YU TW, Kawahashi M, Goda F, Kanaya A, et al
    Anti-Tumor Potential of Selective L-Type Amino Acid Transporter (LAT1) Inhibitor, JPH203, in Patient-Derived Canine Bladder Cancer Organoids.
    Int J Mol Sci. 2026;27:7681.
    

    >> Share

    
    

    
    Int J Urol

40. OGAWA I, Narita T, Shinohara M, Kawashima Y, et al
    Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study.
    Int J Urol. 2026;33:e70636.
    

    >> Share

    
    

    
    Int Urol Nephrol

41. PETRELLI F, Ghidini A, Vavassori I, Rossitto M, et al
    Early versus deferred immunotherapy in urothelial carcinoma: a review of evidence and post-progression survival.
    Int Urol Nephrol. 2026;58:3969-3976.
    

    >> Share

    
    

    
    J Clin Pharmacol

42. MASTERS JC, Jermain B, Liu A, Cesari R, et al
    Population Pharmacokinetics and Exposure-Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors.
    J Clin Pharmacol. 2026;66:e70295.
    

    >> Share

    
    

    
    J Int Med Res

43. FEYISSA M, Baheer Y, Ahmed B, Rosa N, et al
    The use of artificial intelligence and wearable devices in enhanced recovery after surgery pathways following radical cystectomy: A systematic review.
    J Int Med Res. 2026;54:3000605261485388.
    

    >> Share

    
    

    
    J Med Life

44. BUZOIANU MM, Andras I, Giurgiu L, Medan P, et al
    Preoperative predictors of adverse pathological outcomes following radical cystectomy for muscle-invasive bladder cancer in a tertiary referral center.
    J Med Life. 2026;19:578-582.
    

    >> Share

    
    

    
    J Urol

45. MATULEWICZ RS, Gold SA, Nicholson A, Candelieri-Surette D, et al
    Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration.
    J Urol. 2026 Sep 16:101097JU0000000000005312. doi: 10.1097/JU.0000000000005312.
    

    >> Share

    
    

    
    J Vis Exp

46. ZHANG F, Sun B, Guo H
    Risk Factors for Early Postoperative Ileus Following Laparoscopic Radical Cystoprostatectomy.
    J Vis Exp. 2026;.
    

    >> Share

    
    

    
    JCO Oncol Pract

47. BHANVADIA R, Bochner E, Jiang C, Hong AS, et al
    Identification of High-Performing Safety Net Hospitals for Radical Cystectomy: Implications for National Cancer Institute Cancer Center Partnership.
    JCO Oncol Pract. 2026;22:1572-1582.
    

    >> Share

    
    
48. MITTAL K, Mouw KW, Singh P
    Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic.
    JCO Oncol Pract. 2026;22:1508-1516.
    

    >> Share

    
    

    
    Mol Biol Rep

49. KAUSHIK R, Pawar D, Sharma A, Siwach K, et al
    Integrated analysis of VEGFA rs833061 (- 460T > C) promoter polymorphism and serum YKL-40 levels in bladder cancer: evidence of a genotype-phenotype association.
    Mol Biol Rep. 2026;53:1585.
    

    >> Share

    
    

    
    Nature

50. ITAGI P, Schuster SL, Arora S, Persse TW, et al
    Evolution and heterogeneity of lethal metastatic bladder cancer subtypes.
    Nature. 2026 Sep 16. doi: 10.1038/s41586-026-11035.
    

    >> Share

    
    

    
    Oncogene

51. QIAN L, Liu B, Zhang R, Zhang W, et al
    Epithelial tumor suppressor deletion promotes neuroendocrine differentiation in bladder cancer and reveals homoharringtonine as a candidate vulnerability.
    Oncogene. 2026 Sep 16. doi: 10.1038/s41388-026-03975.
    

    >> Share

    
    

    
    Oncol Rep

52. CHUNG YH, Kim D
    [Expression of Concern] RIP kinase?mediated ROS production triggers XAF1 expression through activation of TAp73 in casticin?treated bladder cancer cells.
    Oncol Rep. 2026;56:186.
    

    >> Share

    
    

    
    Orv Hetil

53. KULLMANN T, Kerenyi G, Szepesvary Z
    [Improved efficacy of the uro-oncology care in light of the longitudinal patient flow data of a regional center].
    Orv Hetil. 2026;167:1477-1482.
    

    >> Share

    
    

    
    Pract Radiat Oncol

54. BALLAS LK, Solanki AA, Baumann BC, Dirix P, et al
    Radiation Therapy for Bladder Cancer: An ASTRO Clinical Practice Guideline.
    Pract Radiat Oncol. 2026 Sep 15:S1879-8500(26)00273.
    

    >> Share

    
    

    
    RSC Med Chem

55. LIU JJ, Sun L, Guo DT, Liang YJ, et al
    Maslinic acid derivative induces the death of transitional bladder cancer cells through apoptosis and autophagy via the PI3K-AKT signaling pathway.
    RSC Med Chem. 2026 Sep 16. doi: 10.1039/d6md00435.
    

    >> Share

    
    

    
    Tob Induc Dis

56. DENG J, Yang B, Wu Z, Wu H, et al
    The burden of bladder cancer and kidney cancer attributable to smoking in Latin America and the Caribbean from 1990 to 2023 and projections to 2050.
    Tob Induc Dis. 2026;24.
    

    >> Share

    
    

    
    Urol Oncol

57. GONG M, Shang P
    Comment on "Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice".
    Urol Oncol. 2026;44:725-726.
    

    >> Share

    
    
58. LI J, Chen K, Zhang S, Shen Y, et al
    Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen.
    Urol Oncol. 2026;44:873-886.
    

    >> Share

    
    
59. QU W, Zhu J, Yang Y, Nie F, et al
    Diagnostic value of CEUS-VI-RADS for predicting muscle invasion in bladder cancer: Validation of the scoring system and introduction of tumor-bladder wall contact length as a supplementary quantitative metric.
    Urol Oncol. 2026;44:859-865.
    

    >> Share

    
    
60. ZAHIR M, Sanford DI, Doshi C, Alsyouf M, et al
    Evaluation, etiology, and management of gross hematuria following radical cystectomy and orthotopic neobladder.
    Urol Oncol. 2026;44:617-623.
    

    >> Share

    
    

    
    Urologia

61. MATHEZ W, Vincentelli A, Chaoui I, Bruyere F, et al
    Antidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis.
    Urologia. 2026 Sep 17:3915603261486088. doi: 10.1177/03915603261486088.
    

    >> Share

    
    

    
    Urology

62. HJORT PB, Jensen JB, Ernst A
    Risk of Subsequent Recurrences and Progression in Non-muscle Invasive Bladder Cancer Patients With Early Recurrence.
    Urology. 2026 Sep 12:S0090-4295(26)00580-7. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    

    
    World J Urol

63. PRAT Y, Mahmud H, Tsur A, Laufer M, et al
    Multimodal large language models for bladder tumor detection in cystoscopy: a retrospective benchmarking study.
    World J Urol. 2026;44:670.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share